Conmed CORP Form 4 insider transactions

John E Gallagher, Executive Vice President & CFO of CONMED Corp, reported multiple transactions in common stock on July 15, 2026.

CONMED Corp reports that Director Celine Christine Martin acquired 5,603 Restricted Stock Units (RSUs) on July 1, 2026, under the company's 2025 Long-Term Incentive Plan.

CONMED Corp Director Jeffrey B. Mirviss acquired 5,603 Restricted Stock Units (RSUs) on July 1, 2026, as part of the company's 2025 Long-Term Incentive Plan.

CONMED Corp reports that Director David M. Bronson acquired 668 shares of common stock through a transaction on June 2, 2026.

CONMED Corp reports a Form 4 filing detailing a transaction by Director LaVerne H. Council, involving the acquisition of common stock and restricted stock units.

CONMED Corp Director Kim Kelderman acquired 5,772 Restricted Stock Units (RSUs) on June 1, 2026, as part of the company's 2025 Long-Term Incentive Plan.

CONMED Corp director Charles Farkas reported transactions involving restricted stock units and common stock.

CONMED Corp director Mark Kaye reported the acquisition of 668 Restricted Stock Units (RSUs) and the vesting of 5,772 RSUs on June 2, 2026.

Barbara J. Schwarzentraub, a Director at CONMED Corp, reported the acquisition of 668 shares of common stock and 5,772 Restricted Stock Units (RSUs).

CONMED Corporation CEO Pat Beyer was granted 28,145 restricted stock units as part of an approved equity incentive plan.

An amended SEC filing reveals CONMED Executive VP Brent Lalomia's restricted stock unit grant was corrected to a total of 17,198 units.

An amended SEC Form 4/A reveals CONMED Corp's VP GM Advanced Surgical, Matthew Schabacker, received a corrected grant of 17,471 Restricted Stock Units.

CONMED Corporation's General Counsel, Hollie K. Foust, filed an amended Form 4 to correct her Restricted Stock Unit grant to a total of 18,563 units.

An amended SEC filing reveals CONMED's Executive Vice President of HR, John D. Ferrell, received a corrected grant of 16,926 Restricted Stock Units.

An amended SEC filing reveals CONMED's EVP, Peter K. Shagory, received a corrected grant of 16,926 Restricted Stock Units, including a special award.

CONMED Corporation's VP GM Advanced Surgical, Matthew Schabacker, received 9,827 Restricted Stock Units and 11,646 stock options under the 2025 Long-Term Incentive Plan.

CONMED Corporation's Executive Vice President of HR, John D. Ferrell, received grants of 9,282 Restricted Stock Units and 10,999 stock options as part of the company's 2025 Long-Term Incentive Plan.

Johonna Marie Pelletier, CONMED Corp's Treasurer and VP, Tax, was granted 5,896 Restricted Stock Units under the company's 2025 Long-Term Incentive Plan.

CONMED Corporation's EVP, Strategy & Corporate Development, Peter K. Shagory, was granted 9,282 Restricted Stock Units and 10,999 stock options under the company's 2025 Long-Term Incentive Plan.

CONMED's Executive VP of RA, QA, Brent Lalomia, received 9,554 Restricted Stock Units and 11,322 stock options under the company's 2025 Long-Term Incentive Plan.

CONMED's General Counsel and Corporate Secretary, Hollie K. Foust, was granted 10,919 Restricted Stock Units and 12,940 stock options.

CONMED's VP Corporate Controller, Andrew James Moller, was granted 5,896 Restricted Stock Units under the company's 2025 Long-Term Incentive Plan.

CONMED Corporation's President and CEO, Pat Beyer, received significant equity awards, including 28,800 Restricted Stock Units and 68,258 stock options, under the company's 2025 Long-Term Incentive Plan.

CONMED Director Mark Kaye acquired 152 shares of common stock through the vesting of Restricted Stock Units.

CONMED Corp's Chief Information Officer, Richard Glaze, sold 257 shares of common stock for $41.21 per share, executed under a Rule 10b5-1 trading plan.

CONMED's Chief Information Officer, Richard Glaze, settled vested restricted stock units and subsequently sold a portion of the resulting common stock to cover tax obligations.

CONMED Corporation's Executive Vice President and CFO, Todd W. Garner, reported the sale of 3,500 shares of common stock at $43 per share, executed under a pre-arranged 10b5-1 trading plan.

CONMED's General Counsel, Hollie K. Foust, will acquire 4,000 shares through RSU vesting and subsequently sell 1,114 shares to cover tax obligations on November 4, 2025.

CONMED's Executive Vice President and CFO, Todd W. Garner, exercised restricted stock units and subsequently sold a portion of the resulting common stock to cover tax obligations.

CONMED Corporation Director Charles Farkas sold 2,000 shares of common stock for approximately $107,050 on September 12, 2025, under a pre-arranged trading plan.